-
Published 10/13/2026
Elzieny AA, Alreshq R, Ullah I, Fine D, Teruya S, Helmke S, Gallegos C, Miller EJ, Slivnick JA, Maurer MS, Li B, Ruberg FL. Machine Learning of Echocardiographic Left Ventricular Myocardial Radiomics for Identification of Transthyretin Amyloid Cardiomyopathy. JACC Adv. 2026 Oct 13; 5(11 Pt 2):103336. PMID: 42868962.
-
Published 10/11/2026
McMenamin KJ, Sanchorawala A, Islam S, Prokaeva T, Spencer B, Teruya S, Slivnick J, Alreshq R, Fine D, Helmke S, Gallegos C, Miller EJ, Maurer MS, Ruberg FL. Adverse Outcomes of Transthyretin p.V142I Carriers With Non-Amyloid Heart Failure:The SCAN-MP Study. J Card Fail. 2026 Oct 11. PMID: 42859081.
-
Published 9/4/2026
Kourelis T, Comenzo R, Cortese A, Grodin JL, Grogan M, Milani P, Ruberg FL, Sekijima Y, Weberling LD, Kastritis E, Alexander KM. Susceptibility and screening approaches in systemic amyloidosis: expert perspectives from the International Society of Amyloidosis (ISA). Amyloid. 2026 Sep 04; 1-14. PMID: 42695486.
-
Published 8/30/2026
Ruberg FL, Davis MK, Cuddy SAM, Stern LK, Akinboboye O, Shah K, Sarswat N, Khouri MG, Judge DP, Griffin JM, Grodin JL, Fawaz S, Zeldow B, Tamby JF, Castaño A, Sinha U, Fontana M, Gillmore J, Alexander KM. Long-term effects of acoramidis on mortality in variant transthyretin amyloid cardiomyopathy, including p.Val142Ile: findings from the open-label extension of ATTRibute-CM. Eur J Heart Fail. 2026 Aug 30. PMID: 42669031.
-
Published 8/30/2026
Dorbala S, Maurer MS, Cuddy SAM, AbouEzzeddine OF, Di Carli MF, Dilsizian V, Dispenzieri A, Gallegos-Kattán C, Guthrie S, Mangal B, Hanna M, Khouri MG, Malhotra S, Mitchell JD, Narra RK, Orlandi C, Rosenthal JL, Ruberg FL, Smiley D, Sperry BW, Udelson JE, Weinberg RL, Wall JS, Masri A. 124I-Evuzamitide Positron Emission Tomography/Computed Tomography for Diagnosing Cardiac Amyloidosis: The REVEAL Nonrandomized Clinical Trial. JAMA. 2026 Aug 30. PMID: 42669054.